Publications by authors named "V Subramanyam"

Many agents that show promise in preclinical cancer models lack efficacy in patients due to patient heterogeneity that is not captured in traditional assays. To address this problem, we have developed GENEVA, a platform that measures the molecular and phenotypic consequences of drug perturbations within diverse populations of cancer cells at single-cell resolution, both and . Here, we apply GENEVA to study the KRAS G12C inhibitors, recapitulating known properties of these drugs and uncovering a previously unknown role for mitochondrial activation in cell death induced by KRAS inhibition.

View Article and Find Full Text PDF

Natural products serve as a valuable resource in drug discovery and the identification of bioactive molecules in the field of epimedicine, which targets epigenetic regulator enzymes through epidrugs. In this study, β-1,3-glucan (BG), a natural storage polysaccharide in a well-known immunostimulatory agent, is propounded as a promising epidrug. To elucidate the therapeutic efficacy of BG against ovarian cancer, the molecular interactions between BG and epigenetic regulators, Protein Arginine Methyltransferases (PRMTs) and Sirtuins (SIRTs) were investigated using computational methods followed by gene expression studies in SKOV-3 ovarian cancer cell line.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how cancer cells, particularly pancreatic ductal adenocarcinoma (PDAC), regulate oncogenic protein levels to survive, focusing on the Myc oncogene.
  • Using CRISPRi screens, four RNA binding proteins (RBPs) were identified as key activators of selective translation, with RBM42 being the most critical and linked to poor patient survival.
  • RBM42 was found to be a ribosome-associated protein that binds to the 5' untranslated region (5'UTR) of specific oncogenic transcripts, promoting their translation and supporting cancer growth, offering potential for new therapeutic strategies.
View Article and Find Full Text PDF

Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur and progress. Resistance often emerges through mutations in the therapeutic target or activation of alternative signaling pathways. Mechanisms of acute tumor cell resistance to initial EGFR (EGFRi) or KRAS (G12Ci) pathway inhibition remain poorly understood.

View Article and Find Full Text PDF